| Acetylcholine Receptor Blocking Antibody | 34459X |
|
 |
||
| This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test. | ||
| CPT Code(s): 83519 | Clinical Significance: Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. This assay is most useful when the acetylcholinesterase receptor modulating antibodies are positive. The assay for blocking antibodies is useful in monitoring response to therapy. |
|
| Specimen Container: No additive (red-top) |
| Preferred Specimen: 1 mL serum (0.1 mL minimum) |
| Instructions: Serum is the only acceptable sample. |
| Transport Temperaturer: Room temperature |
| Methodology: Radioimmunoassay |
| Reference Range: <15% of inhibition |
